WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Katherine Forbes
Patent Agent
Patents and Innovations
San Francisco
kforbes@wsgr.com

D858-350-2339

Download vCard
Open PDF

Katherine Forbes is a patent agent in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice.

Before joining the firm, Katherine worked as a medicinal chemist in the pharmaceutical industry and a postdoctoral researcher in chemistry at the University of California, Berkeley. She applies her experience to patent prosecution, freedom-to-operate, and due diligence matters in the life sciences.

Experience

Katherine Forbes is a patent agent in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice.

Before joining the firm, Katherine worked as a medicinal chemist in the pharmaceutical industry and a postdoctoral researcher in chemistry at the University of California, Berkeley. She applies her experience to patent prosecution, freedom-to-operate, and due diligence matters in the life sciences.

Education
  • Postdoctoral Researcher, University of California, Berkeley
  • Ph.D., Chemistry, Harvard University, 2023

    President, Graduate Student and Postdoc Council; Recipient, Harvard University Department of Chemistry and Chemical Biology Community Award; Recipient, Bok Award for Distinction in Teaching; Fellow, Bristol Myers Squibb Graduate Student

  • B.S., Chemistry, Occidental College, 2018
Honors
    • Named to the Forbes 30 Under 30 – Science, 2026
Admissions
  • U.S. Patent and Trademark Office
Credentials
Education
  • Postdoctoral Researcher, University of California, Berkeley
  • Ph.D., Chemistry, Harvard University, 2023

    President, Graduate Student and Postdoc Council; Recipient, Harvard University Department of Chemistry and Chemical Biology Community Award; Recipient, Bok Award for Distinction in Teaching; Fellow, Bristol Myers Squibb Graduate Student

  • B.S., Chemistry, Occidental College, 2018
Honors
    • Named to the Forbes 30 Under 30 – Science, 2026
Admissions
  • U.S. Patent and Trademark Office

Select Publications

  • Co-author, “Enantioselective hydrogen-bond-donor catalysis to access diverse stereogenic-at-P(V) compounds,” 376(6598) Science 1230-1236, 2022
  • Co-author, “Photoredox-Catalyzed Oxidation of Anions for the Atom-Economical Hydro-, Amido-, and Dialkylation of Alkenes,” 87(5) The Journal of Organic Chemistry 3498–3510, 2022
  • Co-author, “Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis,” 64(13) Journal of Medicinal Chemistry 9404–9430, 2021

Select Speaking Engagements

  • Speaker, Genentech Graduate Student Symposium, 2022
  • Speaker, Bristol Myers Squibb Award Symposium, 2023
Insights

Select Publications

  • Co-author, “Enantioselective hydrogen-bond-donor catalysis to access diverse stereogenic-at-P(V) compounds,” 376(6598) Science 1230-1236, 2022
  • Co-author, “Photoredox-Catalyzed Oxidation of Anions for the Atom-Economical Hydro-, Amido-, and Dialkylation of Alkenes,” 87(5) The Journal of Organic Chemistry 3498–3510, 2022
  • Co-author, “Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis,” 64(13) Journal of Medicinal Chemistry 9404–9430, 2021

Select Speaking Engagements

  • Speaker, Genentech Graduate Student Symposium, 2022
  • Speaker, Bristol Myers Squibb Award Symposium, 2023

Therapeutics and Drug Discovery

  • Small molecules

Chemistry

  • Catalysis
  • Medicinal chemistry
  • Organic chemistry
  • Phosphorus chemistry
  • Supramolecular chemistry
Technical Fluency

Therapeutics and Drug Discovery

  • Small molecules

Chemistry

  • Catalysis
  • Medicinal chemistry
  • Organic chemistry
  • Phosphorus chemistry
  • Supramolecular chemistry
Focus Areas
  • Intellectual Property
  • Life Sciences
  • Patents and Innovations
Recent Insights
Client Highlights
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.